Paolo Michieli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3876953/publications.pdf

Version: 2024-02-01

37	3,775	304743	414414
papers	citations	22 h-index	32 g-index

38	38	38	4870
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The NHanceÂ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. Biomedicines, 2021, 9, 665.	3.2	2
2	Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. Oncotarget, 2017, 8, 38193-38213.	1.8	22
3	Dual Constant Domainâ€Fab: A novel strategy to improve halfâ€life and potency of a Met therapeutic antibody. Molecular Oncology, 2016, 10, 938-948.	4.6	11
4	Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy. Scientific Reports, 2016, 6, 31621.	3.3	16
5	ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment.. Journal of Clinical Oncology, 2016, 34, e14016-e14016.	1.6	2
6	Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Research, 2015, 75, 3373-3383.	0.9	32
7	Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs. Cancer Research, 2014, 74, 6598-6609.	0.9	59
8	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 2014, 7, 1940-1955.	6.4	90
9	Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. Journal of Molecular Medicine, 2014, 92, 65-76.	3.9	9
10	Four individually druggable MET hotspots mediate HGF-driven tumor progression. Journal of Clinical Investigation, 2014, 124, 3172-3186.	8.2	42
11	Abstract LB-330: Four individually druggable Met hotspots mediate HGF-driven tumor progression. , 2014, , .		0
12	Abstract 3726: Inhibition of MET overcomes invasive resistance to Bevacizumab and prolongs survival in orthotopic mouse models of glioblastoma multiforme. , 2014, , .		0
13	Tivantinibâ€"a cytotoxic drug in MET inhibitor's clothes?. Nature Reviews Clinical Oncology, 2013, 10, 372-374.	27.6	34
14	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. Clinical Cancer Research, 2013, 19, 2381-2392.	7.0	157
15	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METâ€"Response. Clinical Cancer Research, 2013, 19, 4291-4291.	7.0	12
16	Abstract B082: Role of CD44v6 in acquired resistance to anti-angiogenic therapy of triple-negative breast cancer. , 2013, , .		0
17	Abstract 631: Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. , 2011, , .		0
18	Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody. Journal of Biological Chemistry, 2010, 285, 36149-36157.	3.4	73

#	Article	IF	Citations
19	Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?. Cell Cycle, 2009, 8, 3291-3296.	2.6	60
20	Expression and Functional Regulation of Myoglobin in Epithelial Cancers. American Journal of Pathology, 2009, 175, 201-206.	3.8	74
21	Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. Journal of Clinical Investigation, 2009, 119, 865-875.	8.2	59
22	Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology, 2008, 47, 2010-2025.	7.3	15
23	A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met. Journal of Biological Chemistry, 2008, 283, 21267-21277.	3.4	107
24	Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis. PLoS ONE, 2008, 3, e3223.	2.5	36
25	HGFâ€“MSP chimera protects kidneys from ischemiaâ€“reperfusion injury. Biochemical and Biophysical Research Communications, 2007, 363, 451-456.	2.1	14
26	Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 2004, 6, 61-73.	16.8	282
27	An uncleavable form of proâ€“scatter factor suppresses tumor growth and dissemination in mice. Journal of Clinical Investigation, 2004, 114, 1418-1432.	8.2	85
28	Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3, 347-361.	16.8	1,244
29	Mutations in the met Oncogene Unveil a â€œDual Switchâ€•Mechanism Controlling Tyrosine Kinase Activity. Journal of Biological Chemistry, 2003, 278, 29352-29358.	3.4	41
30	An HGFâ€“MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nature Biotechnology, 2002, 20, 488-495.	17.5	22
31	Different point mutations in the met oncogene elicit distinct biological properties. FASEB Journal, 2000, 14, 399-406.	0.5	93
32	Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene, 1999, 18, 5221-5231.	5.9	139
33	METPRC mutations in the ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. , 1999, 181, 507-514.		24
34	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 1998, 391, 285-288.	27.8	485
35	Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14379-14383.	7.1	96
36	Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.. Journal of Clinical Investigation, 1993, 91, 1753-1760.	8.2	333

#	Article	IF	Citations
37	Taql RFLP of the human tropomyosin gene (TPM3) involved in the generation of the TRK oncogene. Nucleic Acids Research, 1991, 19, 4796-4796.	14.5	5